The study tracked 53 patients, half of whom needed ventilators and four of whom were on heart-lung bypass machines, who received the drug through Gilead’s compassionate use program, according to The Hill.
The study was co-written by researchers from Gilead and hospitals treating COVID-19 patients, according to The Wall Street Journal.
The drugs were given to patients between Jan. 25 and March 27, and 36 patients saw clinical improvement, 25 were discharged and seven died.
Of patients using ventilators, 17 had their tubes disconnected after remdesivir treatment. Three out of four patients on life-support machines were able to be taken off them, according to the Journal.
More than half of the patients experienced side effects ranging from a rash to acute kidney injury, according to NPR.
The study itself doesn’t prove remdesivir’s effectiveness, as more large clinical trials are needed, according to the Journal.
Several larger studies on the drug are expected to post results within weeks.
More articles on pharmacy:
Johnson & Johnson warns of temporary Tylenol shortage
A breakdown of 6 of the most promising COVID-19 treatments
Employees test positive for COVID-19 at mail-order VA pharmacy in South Carolina
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.